Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

890
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
890
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents01:17

Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents

809
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
809
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

871
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
871
Other Disorders of Digestive System01:30

Other Disorders of Digestive System

1.6K
The gastrointestinal tract is susceptible to various disorders. If the lower esophageal sphincter is damaged, stomach acid can flow back into the esophagus, causing irritation and inflammation of the lining. This condition is called gastroesophageal reflux disease (known as heartburn) and may cause chest pain and difficulty swallowing. In the stomach, prolonged use of nonsteroidal anti-inflammatory drugs like aspirin, chronic alcohol consumption, bacterial infections such as Helicobacter...
1.6K
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

1.3K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.3K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
893

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interleukin-13 Promotes Accumulation of Esophageal Epithelial Mitochondria With Translational Implications for Eosinophilic Esophagitis.

Cellular and molecular gastroenterology and hepatology·2026
Same author

Efficacy and Safety of Domperidone for Patients With Symptoms of Gastroparesis; Long-Term Results.

Neurogastroenterology and motility·2026
Same author

Autophagy Reprogramming in Cancer.

Journal of cellular physiology·2025
Same author

Unusual Instance of Primary Diffuse Large B-cell Lymphoma of the Colon.

Cureus·2023
Same author

Characteristics and outcomes of patients with gastroparesis using enteral and/or exclusive parenteral nutrition.

JPEN. Journal of parenteral and enteral nutrition·2023
Same author

Association Between Helicobacter pylori and Steatosis Severity on Transient Elastography.

Cureus·2023

Related Experiment Video

Updated: Mar 14, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

627

Cannabinoids and GI Disorders: Endogenous and Exogenous.

Zachary Wilmer Reichenbach1,2, Ron Schey3

  • 1Center for Substance Abuse Research (CSAR), Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.

Current Treatment Options in Gastroenterology
|October 5, 2016
PubMed
Summary

Cannabinoids are a widespread signaling system with significant implications for the gastrointestinal tract. Further research is crucial to understand their role in health and disease, targeting cannabinoid receptors for therapeutic advancements.

Keywords:
CB1 receptorCB2 receptorCannabinoidsGI motilityGPR55Irritable bowel syndrome (IBS)Visceral hypersensitivity

More Related Videos

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
14:25

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans

Published on: September 21, 2019

7.7K
Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research
03:48

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research

Published on: March 1, 2024

1.7K

Related Experiment Videos

Last Updated: Mar 14, 2026

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

627
Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
14:25

Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans

Published on: September 21, 2019

7.7K
Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research
03:48

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research

Published on: March 1, 2024

1.7K

Area of Science:

  • Endocrinology and Pharmacology
  • Gastroenterology

Background:

  • Cannabinoids represent a ubiquitous endogenous signaling system present across multiple organ systems.
  • The identification of cannabinoid receptors in the 1990s established key targets for translational research.
  • Existing therapeutics often address only a single component of the complex cannabinoid system.

Approach:

  • This review explores the current understanding and future research directions for cannabinoids within the gastrointestinal tract.
  • It highlights the potential of targeting cannabinoid receptors for novel therapeutic strategies.
  • The focus is on expanding research beyond the nervous system to encompass the digestive system.

Key Points:

  • Cannabinoids play a vital role in maintaining gastrointestinal homeostasis.
  • Dysregulation of the cannabinoid system is implicated in various gastrointestinal disorders.
  • Targeting cannabinoid receptors offers a promising avenue for treating gastrointestinal diseases.

Conclusions:

  • The medical community must recognize the widespread physiological roles of cannabinoids.
  • Continued research into the gastrointestinal cannabinoid system is essential for advancing therapeutic interventions.
  • Exploring the full potential of the cannabinoid system can lead to novel treatments for digestive system conditions.